Targeted Alpha Therapy Using Astatine (At-211) Against Differentiated Thyroid Cancer

NCT05275946 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
11
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Osaka University